pharma · Colitis, Ulcerative · Multiple Myeloma
Janssen Cilag International
Janssen Cilag International NV
Janssen-Cilag Farmaceutica Ltda is a pharma organization headquartered in São Paulo, EU. Primary therapeutic focus areas include Colitis, Ulcerative, Multiple Myeloma, Diabetes Mellitus, Type 2, Depressive Disorder, Majo
São Paulo, EU HQ
13 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- São Paulo, EU
- Employees
- 13
- Programs
- 46
- Drugs
- 37
- Patents
- 0
Lumicitabine
Phase 2 · small molecule · Respiratory Syncytial Viruses
Lumicitabine for Respiratory Syncytial Viruses is a Phase 2 program (small_molecule) at Janssen Cilag International NV with 1 ClinicalTrials.gov record(s).
Internal code CR108367
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Janssen Cilag International NV
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Respiratory Syncytial Viruses
- Status
- terminated
- Trials
- 1